Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324676 | 0.89 | MAPT (0.34) | MAPTKMT2A | |
| SCHEMBL6331247 | 0.86 | MAPT (0.32) | MAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL6331222 | 0.81 | HTT (0.43) | MAPTSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL6326292 | 0.78 | KMT2A (0.36) | MAPTSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL6326309 | 0.78 | ALDH1A1 (0.35) | MAPTSMN1; SMN2KMT2APOLBTSHR | |
| SCHEMBL6325427 | 0.78 | MAPT (0.32) | MAPTKMT2ALMNATSHR | |
| SCHEMBL6334979 | 0.78 | MAPT (0.32) | MAPT | |
| SCHEMBL6335008 | 0.78 | UGCG (0.35) | MAPTSMN1; SMN2KMT2APOLBMYC | |
| SCHEMBL6328454 | 0.75 | SIRT6 (0.36) | MAPTKMT2APOLBMEN1LMNA | |
| SCHEMBL6326681 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936570-B2 | Tetrazolinone derivatives | NIHON BAYER AGROCHEM, K.K. (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20040242895-A1 | Novel tetrazolinone derivatives | YANAGI AKIHIKO (JP) | 2004-12-02 | — | — | US | disclosed |
| US-6790810-B2 | Tetrazolinone derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20040102635-A1 | Novel tetrazolinone derivatives | YANAGI AKIHIKO (JP) | 2004-05-27 | — | — | US | disclosed |
| US-6624121-B1 | Exemplified by 2-cyano-3-cyclopropyl-1-(3-((4-cyclopropyl-4,5-dihydro-5-oxo-1H-tetrazol-1 -yl)methyl)-2, 4-dichlorophenyl)propan-1,3-dione | NIHON BAYER AGROCHEM K.K. (JP) | 2003-09-23 | — | — | US | disclosed |
| EP-1208090-A1 | HERBICIDALTETRAZOLINONE DERIVATIVES | NIHON BAYER AGROCHEM K.K. (JP) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001010850-A1 | HERBICIDAL TETRAZOLINONE DERIVATIVES | NIHON BAYER AGROCHEM K.K. (DE) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102635-A1 | Novel tetrazolinone derivatives | CBR1, CBR3, CYP1B1 | MAPT 4318/4885SMN1; SMN2 4200/4885KMT2A 2267/4885 |
| US-20040242895-A1 | Novel tetrazolinone derivatives | CBR3, CBR1, CYP1B1 | MAPT 4327/4885SMN1; SMN2 4203/4885KMT2A 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.